慢性淋巴细胞白血病的一线治疗：阿仑单抗的作用。
First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.
机构信息
Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA;
出版信息
Onco Targets Ther. 2010 Jun 24;3:53-67. doi: 10.2147/ott.s3099.
The CD52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chronic lymphocytic leukemia (CLL), particularly in patients with high-risk features and adverse prognosis. In the CAM307 study alemtuzumab was tested and finally approved as a first-line single agent, even though the hurdle with chlorambucil as the contender was not set very high. Within clinical trials, the drug demonstrated an excellent ability to eliminate minimal residual disease in blood and bone marrow, which has been correlated with a corresponding survival advantage in patients. However, in the maintenance setting, infectious complications due to severe T cell suppression have been highlighted and do not allow clinicans to use alemtuzumab outside of clinical trials. This review discusses potential therapeutic niches and future applications of alemtuzumab with a focus on CLL front-line treatment.
CD52 靶向抗体阿仑单抗在临床实践中具有令人信服的活性，尤其对复发和难治性慢性淋巴细胞白血病（CLL）患者，特别是对具有高危特征和不良预后的患者。在 CAM307 研究中，阿仑单抗被测试并最终被批准为一线单药治疗，尽管氯苯丁酸作为竞争者的门槛设得并不高。在临床试验中，该药物表现出清除血液和骨髓中微小残留疾病的优异能力，这与患者的相应生存优势相关。然而，在维持治疗中，由于严重的 T 细胞抑制导致的感染并发症已被强调，并且不允许临床医生在临床试验之外使用阿仑单抗。这篇综述讨论了阿仑单抗的潜在治疗领域和未来在 CLL 一线治疗中的应用。
Zotero 插件